Aims:
This study aims to explore the potential mechanism by which Botulinum toxin type A (BoNT/
A) inhibits microglial inflammatory activation through P2X7 receptors (P2X7R).
Background:
BoNT/A is a promising analgesic drug, and previous studies have established that it alleviates
Neuropathic Pain (NP) by inhibiting microglial inflammatory activation. This study examined the biomarkers
and potential mechanisms by which BoNT/A relieves neuropathic pain by mediating microglial P2X7R and analyzing
transcriptome sequencing data from mouse BV-2 microglial cells.
Objective:
The P2X7R agonist Bz-ATP was used to induce microglial inflammatory activation, whilst RNAseq
technology was used to explore the biomarkers and potential mechanisms through which BoNT/A suppresses
microglial inflammation.
Methods:
RNA sequencing was performed on three BV-2 cell samples treated with a P2X7R specific activator
(Bz-ATP) and three BV-2 cell samples pre-treated with BoNT/A. Only data that successfully passed quality
control measures were included in subsequent analysis. Initially, Differentially Expressed Genes (DEGs) were
identified from BoNT/A and control samples, followed by Gene Ontology (GO) and Kyoto Encyclopedia of
Genes and Genomes (KEGG) enrichment analyses. Biomarkers were then identified by constructing a Protein-
Protein Interaction (PPI) network and utilizing the CytoHubba plug-in in Cytoscape software. Lastly, enrichment
analysis and regulatory network analysis were performed to elucidate the potential mechanism of
BoNT/A in the treatment of NP.
Results:
93 DEGs related to the “cell component size regulation” GO term and enriched in the “axon guidance”
KEGG pathway were identified. Subsequently, 6 biomarkers were identified, namely PTPRF, CHDH,
CKM, Ky, Sema3b, and Sema3f, which were enriched in pathways related to biosynthesis and metabolism, disease
progression, signal transduction, and organelle function, including the “ribosome” and “Wnt signaling
pathway.” Finally, a competing endogenous RNA (ceRNAs) network was constructed from 6 mRNAs, 66
miRNAs, and 31 lncRNAs, forming a complex relationship network.
Conclusion:
Six genes (PTPRF, Sema3b, Sema3f, CHDH, CKM, and Ky) were identified as biomarkers of microglial
inflammatory activation following BoNT/A treatment. This finding may provide a valuable reference
for the relief and treatment of neuropathic pain.